PsO Pipeline Watch: ART26.12 Shows Promise in In Vitro and In Vivo Psoriasis Models
Artelo Biosciences, Inc.’s ART26.12 showed promise in both in vitro and in vivo psoriasis models, according to a new study in the Journal of Investigative Dermatology.